Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. Navarra, S. V. et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377, 721–731 (2011).
2. Manzi, S. et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity across multiple organ domains: combined efficacy results from the phase 3 BLISS-52 and -76 studies [abstract 1456]. Arthritis Rheum. 62 (Suppl.), S607 (2010).
3. US Food and Drug Administration. FDA approves Benlysta to treat lupus
[online]
, (2011).
4. Wallace, D. J. et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 61, 1168–1178 (2009).
5. Stohl, W., Scholz, J. L. & Cancro, M. P. Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside. Curr. Opin. Rheumatol. doi:10.1097/BOR.0b013e328344c15e.
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献